Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

PURPOSE: Surgery often represents the best chance for disease control in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN). We investigated dual immune-checkpoint inhibition [anti–PD-1, nivolumab (N), and anti-KIR, lirilumab (L)] before and after salvage surgery to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Glenn J., O'Neill, Anne, Shin, Kee-Young, Wong, Kristine, Jo, Vickie Y., Quinn, Charles T., Cutler, Jennifer M., Flynn, Michelle, Lizotte, Patrick H., Annino, Donald J., Goguen, Laura A., Kass, Jason I., Rettig, Eleni M., Sethi, Rosh K.V., Lorch, Jochen H., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Everett, Peter C., Desai, Anupam M., Cavanaugh, Megan E., Paweletz, Cloud P., Egloff, Ann Marie, Uppaluri, Ravindra, Haddad, Robert I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401515/
https://www.ncbi.nlm.nih.gov/pubmed/34667025
http://dx.doi.org/10.1158/1078-0432.CCR-21-2635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401515/
https://www.ncbi.nlm.nih.gov/pubmed/34667025
http://dx.doi.org/10.1158/1078-0432.CCR-21-2635

Ejemplares similares